Tuesday, January 16, 2024 4:50:17 PM
Morning news Today the/ Shorts piled in:((
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost
NEWPORT BEACH, Calif., Jan. 16, 2024 -- InvestorsHub NewsWire -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc., [Nasdaq: INMB]. The licensing agreement grants Elevai a license to use INmune Bio's proprietary "EMx" technology, developed by INmune Bio, Inc., CMO, Mark Lowdell, PhD, that enables Elevai to manufacture current Good Manufacturing Practice ("cGMP") grade, human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost to Elevai than purchasing hucMSCs outright. Manufactured hucMSCs can be incorporated into certain licensed topical cosmetic products sold in the medical aesthetics skincare market.
Elevai believes incorporating the "EMx" technology into its operations is a step towards the company's goal of achieving vertical manufacturing integration, while also expanding long-term production capabilities and lowering overall costs. Ultimately, Elevai believes controlling its processes through its product pipeline with what it believes to be efficient technologies like "EMx" will allow greater stem cell consistency, purity, and propel Elevai's branded cosmetic products further to maintain the company's position as an industry innovator in the medical aesthetics skincare marke
Recent ELAB News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:01:35 PM
- Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity • GlobeNewswire Inc. • 05/02/2024 12:30:00 PM
- Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare • GlobeNewswire Inc. • 05/01/2024 08:00:00 PM
- Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments • GlobeNewswire Inc. • 05/01/2024 01:00:00 PM
- Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments • GlobeNewswire Inc. • 04/29/2024 01:45:37 PM
- ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results • GlobeNewswire Inc. • 03/29/2024 04:00:00 PM
- Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • InvestorsHub NewsWire • 03/18/2024 12:51:03 PM
- ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office • GlobeNewswire Inc. • 01/24/2024 01:30:00 PM
- ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach • InvestorsHub NewsWire • 01/17/2024 02:07:02 PM
- ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach • GlobeNewswire Inc. • 01/17/2024 01:30:00 PM
- ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology • InvestorsHub NewsWire • 01/16/2024 03:05:05 PM
- ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
- ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences • GlobeNewswire Inc. • 01/02/2024 02:15:00 PM
- Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 12/11/2023 02:15:00 PM
- ELEVAI Labs, Inc. Expands International Distribution into Europe • GlobeNewswire Inc. • 12/07/2023 02:41:56 PM
- Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products • GlobeNewswire Inc. • 11/29/2023 02:00:00 PM
- ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public Offering • PR Newswire (US) • 11/24/2023 06:38:00 PM
- Univest Securities, LLC Announces Closing of $6 Million Initial Public Offering of Common Stock for its Client ELEVAI Labs Inc. (Nasdaq: ELAB) • GlobeNewswire Inc. • 11/24/2023 05:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM